https://www.selleckchem.com/products/sn-001.html Anterior mediastinal cysts (AMC) are often misdiagnosed as thymomas and undergo surgical resection, which caused unnecessary treatment and medical resource waste. The purpose of this study is to explore potential possibility of computed tomography (CT)-based radiomics for the diagnosis of AMC and type B1 and B2 thymomas. A group of 188 patients with pathologically confirmed AMC (106 cases misdiagnosed as thymomas in CT) and thymomas (82 cases) and underwent routine chest CT from January 2010 to December 2018 were retrospectively analyzed. The lesions were manually delineated using ITK-SNAP software, and radiomics features were performed using the artificial intelligence kit (AK) software. A total of 180 tumour texture features were extracted from enhanced CT and unenhanced CT, respectively. The general test, correlation analysis, and LASSO were used to features selection and then the radiomics signature (radscore) was obtained. The combined model including radscore and independent clinical factors was deval tool to facilitate the differential diagnosis of AMC and type B1 and B2 thymomas. Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000mg/dL (11.3mmol/L), who often suffer from acute pancreatitis. Pemafibrate is a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα) which has been developed as an affordable oral tablet in Japan. We herein report the first three patients with severe hypertriglyceridemia who were successfully treated with pemafibrate. Three patients with fasting serum triglyceride (TG) levels above 1,000mg/dL (11.3mmol/L) were treated with pemafibrate (0.2-0.4mg/day, 0.1-0.2mg BID). Serum TGs decreased from 2,000-3,000mg/dL (22.6-33.9mmol/L) to < 250mg/dL (2.8mmol/L) without adverse effects in all three patients. Serum TGs in Patient 1 and 2 decreased from 1,32